Category: 97859-49-9

Cardillo, Giuliana; Orena, Mario; Sandri, Sergio; Tomasini, Claudia published an article in 1987, the title of the article was An efficient synthesis of (R)-(+)- and (S)-(-)-propranolol from resolved 5-(iodomethyl)oxazolidin-2-ones.Product Details of 97859-49-9 And the article contains the following content:

Oxazolidinones I and II were prepared by cyclization of (S)-PhCHMeNHCH2CH:CH2.HBr with iodine and Amberlyst A 26 in the CO3- form. I and II were converted in 8 steps to (S)-(-)- and (R)-(+)-propranolol, resp. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Product Details of 97859-49-9

The Article related to propranolol diastereomer, oxazolidinone iodomethyl preparation resolution, iodomethyloxazolidinone diastereomer preparation conversion propranolol, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Alcohols and Thiols and other aspects.Product Details of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On March 12, 2014, Lv, Binhua; Li, Chengwei published a patent.Application of 97859-49-9 The title of the patent was Preparation of substituted oxazolidinone compounds as factor Xα inhibitors. And the patent contained the following:

The present invention relates to substituted oxazolidinone compounds I [wherein R1 = 5-(un)substituted 2-thienyl or 4-(un)substituted Ph; R2 = 3-oxo-4-morpholinyl, 2-oxo-1-piperidinyl, etc.; R3 and R4 = independently H, D, F, Cl, OH, CN, etc.; R5 and R6 = independently H, D, F, Cl, OH, etc.; with proviso], pharmaceutically acceptable salts, crystal forms, hydrates, or solvates thereof as factor Xα inhibitors for treating and/or preventing thromboembolic diseases. For example, II was prepared in a multi-step synthesis. The title compounds showed inhibitory activity with IC50 < 50 nM against human blood-coagulation factor Xα. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Application of 97859-49-9

The Article related to preparation oxazolidinone factor xa inhibitor treatment thromboembolic disease human, Heterocyclic Compounds (More Than One Hetero Atom): Oxazines (Including Morpholine) and other aspects.Application of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On February 27, 2014, Lv, Binhua; Li, Chengwei; Cao, Benwen published a patent.Electric Literature of 97859-49-9 The title of the patent was Preparation of substituted oxazolidinone compounds as factor Xα inhibitors. And the patent contained the following:

The present invention relates to substituted oxazolidinone compounds I [wherein R1 = 5-(un)substituted 2-thienyl or 4-(un)substituted Ph; R2 = 3-oxo-4-morpholinyl, 2-oxo-1-piperidinyl, etc.; R3 and R4 = independently H, D, F, Cl, OH, CN, etc.; R5 and R6 = independently H, D, F, Cl, OH, etc.; with proviso], pharmaceutically acceptable salts, crystal forms, hydrates, or solvates thereof as factor Xα inhibitors for treating and/or preventing thromboembolic diseases. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 0.002 nM against human blood-coagulation factor Xα. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Electric Literature of 97859-49-9

The Article related to preparation oxazolidinone factor xa inhibitor treatment thromboembolic disease human, Heterocyclic Compounds (More Than One Hetero Atom): Oxazines (Including Morpholine) and other aspects.Electric Literature of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On December 13, 2018, Peer Mohamed, Shahul Hameed; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi; Venkataraman, Balasubramanian published a patent.Product Details of 97859-49-9 The title of the patent was Preparation of heterocyclic derivatives for use as antibacterial agents. And the patent contained the following:

Title compounds I [R1 = (un)substituted alkyl, alkenyl, cycloalkyl, etc.; R2 and R3 independently = H, F, OH, alkyl, etc.; R8 = H, F, or alkyl; R9 = H, F, CN, OH, or alkyl; L = N, CH, CCN, C-halo, etc.; M = CH or alkyl; each X and Y independently = N, CH, CCN, etc.; Z = O, S, or CH2; m = 0 or 1; n = 0 to 2; with provisions], and their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, are prepared and disclosed as antibacterial agents. Thus, e.g., II was prepared by a multistep procedure (preparation given). I were evaluated in S. aureus (ATCC 29213) antibacterial activity assays, e.g., II demonstrated a <4 μg/mL min. inhibitory concentration in LB media. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Product Details of 97859-49-9

The Article related to heterocyclic preparation antibacterial agent, pyridooxazinone preparation antibacterial agent, Heterocyclic Compounds (More Than One Hetero Atom): Oxazines (Including Morpholine) and other aspects.Product Details of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On June 15, 2018, Peer Mohamed, Shahul Hameed; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi published a patent.COA of Formula: C4H7NO3 The title of the patent was Preparation of heterocyclic derivatives for use as antibacterial agents. And the patent contained the following:

Title compounds I [R1 = (un)substituted alkyl, alkenyl, cycloalkyl, etc.; R2 and R3 independently = H, F, OH, alkyl, etc.; R8 = H, F, or alkyl; R9 = H, F, CN, OH, or alkyl; L = N, CH, CCN, C-halo, etc.; M = CH or alkyl; each X and Y independently = N, CH, CCN, etc.; Z = O, S, or CH2; m = 0 or 1; n = 0 to 2; with provisions], and their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, are prepared and disclosed as antibacterial agents. Thus, e.g., II was prepared by a multistep procedure (preparation given). I were evaluated in S. aureus (ATCC 29213) antibacterial activity assays, e.g., II demonstrated a <4 μg/mL min. inhibitory concentration in LB media. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).COA of Formula: C4H7NO3

The Article related to heterocyclic preparation antibacterial agent, pyridooxazinone preparation antibacterial agent, Heterocyclic Compounds (More Than One Hetero Atom): Oxazines (Including Morpholine) and other aspects.COA of Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On May 11, 2017, Li, Siyuan; Gui, Shaoxiao; Zhang, Jicheng; Huang, Luning; Tao, Anping; Gu, Hong published a patent.Computed Properties of 97859-49-9 The title of the patent was Preparation method for tedizolid and its intermediate. And the patent contained the following:

The present invention relates to a preparation method for a tedizolid compound in Formula I. In Formula I, R is selected from hydrogen, benzyl or benzyl substituted by a substituent, the substituent is selected from a group consisting of halogen, nitryl, C1-C6 alkyl, and C1-C6 alkoxy, and R1 is C1-C6 alkyl or C1-C6 alkyl substituted by halogen. The method comprises: generating a compound having a structure with formula II and a compound having a structure with formula III by a coupled reaction under the catalysis of a metal catalyst, a substituent of R being defined as above, where X is a leaving group, the leaving group comprising chlorine, bromine, iodine, sulfonyl oxy such as trifluoromethane sulfonic oxy, methylsulfonyl oxy and benzenesulfonyl oxy, or benzenesulfonyl oxy substituted by one or more substituents, the substituent being selected from a group consisting of halogen, C1-C6 alkyl, and C1-C6 alkoxy. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Computed Properties of 97859-49-9

The Article related to tedizolid preparation, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Computed Properties of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On May 10, 2017, Li, Siyuan; Gui, Shaoxiao; Zhang, Jicheng; Huang, Luning; Tao, Anping; Gu, Hong published a patent.Formula: C4H7NO3 The title of the patent was Preparation method for tedizolid and its intermediate. And the patent contained the following:

The invention relates to a preparation method for a tedizolid compound in Formula I. In Formula I, R is selected from hydrogen, benzyl or benzyl substituted by a substituent, the substituent is selected from a group consisting of halogen, nitryl, C1-C6 alkyl, and C1-C6 alkoxy, and R1 is C1-C6 alkyl or C1-C6 alkyl substituted by halogen. The method comprises: generating a compound having a structure with formula II and a compound having a structure with formula III by a coupled reaction under the catalysis of a metal catalyst, a substituent of R being defined as above, where X is a leaving group, the leaving group comprising chlorine, bromine, iodine, sulfonyl oxy such as trifluoromethane sulfonic oxy, methylsulfonyl oxy and benzenesulfonyl oxy, or benzenesulfonyl oxy substituted by one or more substituents, the substituent being selected from a group consisting of halogen, C1-C6 alkyl, and C1-C6 alkoxy. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Formula: C4H7NO3

The Article related to tedizolid preparation, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On January 4, 2019, Peer Mohamed, Shahul Hameed; Bharatham, Nagakumar; Katagihallimath, Nainesh; Sharma, Sreevalli; Nandishaiah, Radha; Ramachandran, Vasanthi published a patent.SDS of cas: 97859-49-9 The title of the patent was Preparation of anti-bacterial heterocyclic compounds. And the patent contained the following:

The title compounds I [R1 = alkyl, cycloalkyl, alkylamino, etc.; R2 = H, F, Cl, etc.; R3 = H, alkyl, F, etc.; X1 = N or CR4 (wherein R4 = H, halo, cyano, etc.); X2 = N or CR5 (R5 = H, halo, cyano, etc.); X3 = N or CR6; and X4 = CR6 when dotted line represents a bond (R6 = H, cyano, alkyl, etc.); or X3 = CH2 or O; and X4 = CH2 when dotted line represents no bond; n = 0-2; Y1 and Y2 = (independently) N or CR7 (R7 = H, halo, cyano, etc.); Z1 = O, S, NH, CH2; R8 = H, OH, alkyl, F] along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharmaceutically active derivatives thereof, useful for killing or inhibiting the growth of a microorganism selected from the group consisting of bacteria, virus, fungi, and protozoa, were prepared E.g., a multi-step synthesis of (S)-II, starting 6-methoxy-1,5-naphthyridin-4-ol and chloro(chloromethyl)dimethylsilane, was described. Exemplified compounds I were tested for their antibacterial activity (data given). Pharmaceutical compositions comprising compound I, alone and in combination with at least one antibiotic, were disclosed. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).SDS of cas: 97859-49-9

The Article related to heterocyclic compound pyridooxazinone pyrazinooxazinone preparation antibacterial antiviral antifungal protozoacide, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.SDS of cas: 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On August 4, 2011, Hoffmann, Matthias; Dahmann, Georg; Fiegen, Dennis; Handschuh, Sandra; Klicic, Jasna; Linz, Guenter; Schaenzle, Gerhard; Schnapp, Andreas; East, Stephen P.; Mazanetz, Michael Philip; Scott, John; Walker, Edward published a patent.COA of Formula: C4H7NO3 The title of the patent was Preparation of substituted naphthyridines and their use as therapeutic Syk kinase inhibitors. And the patent contained the following:

The invention relates to new substituted naphthyridines of formula I, as well as pharmacol. acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is -O-R3 or -NR3R4, R3 is substituted C1-6-alkyl, R4 is H or C1-6-alkyl, and R2 is H, (un)substituted 5-10-membered aryl, (un)substituted 5-10-membered heteroaryl, etc., as well as pharmaceutical compositions containing these compounds Naphthyridines of formula I are particularly suitable for the treatment of respiratory complaints, allergic diseases, osteoporosis, gastrointestinal diseases, autoimmune diseases, inflammatory diseases and diseases of the peripheral or central nervous system, particularly for the treatment of asthma, allergic rhinitis, rheumatoid arthritis, allergic dermatitis and COPD. Synthetic procedures for preparing I are exemplified. Example compound II, prepared by reacting (R)-4-((R)-1-hydroxyethyl)pyrrolidine-2-one and III, had an IC50 of 0.0131 μM in an Syk kinase luminescence assay. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).COA of Formula: C4H7NO3

The Article related to preparation naphthyridine syk kinase inhibitor therapy, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.COA of Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On February 11, 2021, Harikrishnan, Lalgudi S.; Park, Peter Kinam; Ruan, Zheming; Wei, Donna D.; O’Malley, Daniel; Wan, Honghe; Purandare, Ashok Vinayak; Fink, Brian E. published a patent.COA of Formula: C4H7NO3 The title of the patent was Preparation of substituted benzamides as RORγ agonists for the treatment of cancer. And the patent contained the following:

The invention is directed to compounds of the formula I wherein X is N and CR5; R5 is H, CN, halo, etc.; Y is CR6; R6 is H, CN, halo, etc.; R1 is (CH2)0-2-NHCOO-(CRxRy)0-4-R1a,(CH2)0-2-NHCORx-(CRxRy)0-4-R1a, 4-10 membered heterocycle-(CRxRy)0-4-R1a, etc.; each Rx and Ry are independently H and C1-3 alkyl; R1a is H, CF3, OH, etc.; R2 and R3 are independently H, halo and C1-3 alkyl; R4 is C1-6 alkyl, C1-6 alkenyl, C1-6 haloalkyl, etc.; and stereoisomers and pharmaceutically acceptable salt thereof; their preparation and use for the treatment of cancer. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their RORγ agonistic activity. From the assay, it was determined that compound II exhibited EC50 value of 1.7 nM. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).COA of Formula: C4H7NO3

The Article related to benzamide preparation ror gamma agonist treatment cancer, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.COA of Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem